Literature DB >> 1744122

A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein.

M K O'Banion1, H B Sadowski, V Winn, D A Young.   

Abstract

The profound influence of glucocorticoid hormones on the inflammatory response includes a rapid and significant reduction in the synthesis of cyclooxygenase (prostaglandin G/H synthase, PGHS), the key enzyme for prostaglandin biosynthesis. In analyzing the glucocorticoid effects on PGHS synthesis in C127 mouse fibroblasts, we detected a novel 4-kilobase (kb) mRNA that is related to a PGHS cDNA cloned from an ovine seminal vesicle library. This RNA is much more prevalent in cycloheximide-treated cells and, based on stringency analysis and preliminary sequence data, arises from a gene distinct from that transcribed into the previously cloned 2.8-kb PGHS cDNA. Furthermore, the 4-kb mRNA encodes a 70-kDa protein that is specifically immunoprecipitated by anti-PGHS serum. The abundance of the 4-kb mRNA is strongly decreased by dexamethasone and increased by serum within 2 h whereas the 2.8-kb PGHS mRNA, which is also seen in these cells, does not consistently change. These changes in the level of the 4-kb mRNA with serum and dexamethasone treatment parallel changes in the level of synthesized PGHS protein detected in both metabolically labeled cells and in in vitro translated mRNAs. This discovery of a cyclooxygenase-related gene that is transcriptionally regulated by serum and glucocorticoid hormones in a manner identical to that reported for cyclooxygenase activity may help clarify issues regarding cyclooxygenase regulation and suggests that two distinct and differentially regulated cyclooxygenase species exist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744122

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs.

Authors:  D L Simmons; R M Botting; P M Robertson; M L Madsen; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.

Authors:  B J Whittle
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 3.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 4.  Recent methodologies toward the synthesis of valdecoxib: a potential 3,4-diarylisoxazolyl COX-II inhibitor.

Authors:  Sureshbabu Dadiboyena; Adel Nefzi
Journal:  Eur J Med Chem       Date:  2010-08-06       Impact factor: 6.514

5.  cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.

Authors:  M K O'Banion; V D Winn; D A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 6.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

Review 7.  [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].

Authors:  D O Stichtenoth; H Zeidler; J C Frölich
Journal:  Med Klin (Munich)       Date:  1998-07-15

8.  Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide.

Authors:  L Feng; Y Xia; G E Garcia; D Hwang; C B Wilson
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.

Authors:  J Wilborn; L J Crofford; M D Burdick; S L Kunkel; R M Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Strong activation of cyclooxygenase I and II catalytic activity by dietary bioflavonoids.

Authors:  Hyoung-Woo Bai; Bao Ting Zhu
Journal:  J Lipid Res       Date:  2008-07-26       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.